Sangamo Therapeutics (SGMOQ) Other Non-Current Liabilities (2013 - 2025)

Sangamo Therapeutics has reported Other Non-Current Liabilities for 10 years, with the latest figure at $580000.0 in Q4 2025.

• On a quarterly basis, Other Non-Current Liabilities fell 37.83% year-over-year to $580000.0 in Q4 2025; TTM through Dec 2025 was $580000.0, a 37.83% decrease from a year earlier, with the FY2025 full-year figure at $580000.0, down 37.83% from the prior year.
• Other Non-Current Liabilities was $580000.0 for Q4 2025 at Sangamo Therapeutics, down from $977000.0 in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $7.6 million in Q3 2021, with the low at $580000.0 in Q4 2025.
• Average Other Non-Current Liabilities over 5 years is $2.1 million, with a median of $1.2 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Other Non-Current Liabilities increased 22.93% in 2021, then slumped 82.9% in 2022.
• Over 5 years, Other Non-Current Liabilities stood at $1.2 million in 2021, then dropped by 0.82% to $1.2 million in 2022, then dropped by 1.66% to $1.2 million in 2023, then decreased by 21.4% to $933000.0 in 2024, then slumped by 37.83% to $580000.0 in 2025.
• The last three Other Non-Current Liabilities figures came in at $580000.0 (Q4 2025), $977000.0 (Q3 2025), and $962000.0 (Q2 2025), per Business Quant data.